MARKET

MNPR

MNPR

Monopar Therapeutics Inc
NASDAQ
58.27
+0.52
+0.90%
Closed 17:23 02/09 EST
OPEN
57.41
PREV CLOSE
57.75
HIGH
58.45
LOW
54.90
VOLUME
387.87K
TURNOVER
0
52 WEEK HIGH
105.00
52 WEEK LOW
26.06
MARKET CAP
389.39M
P/E (TTM)
-16.9528
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MNPR last week (0202-0206)?
Weekly Report · 1d ago
Monopar Therapeutics Price Target Maintained With a $104.00/Share by BTIG
Dow Jones · 02/02 13:07
BTIG Reiterates Buy on Monopar Therapeutics, Maintains $104 Price Target
Benzinga · 02/02 13:01
MNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease
TipRanks · 02/02 11:46
Weekly Report: what happened at MNPR last week (0126-0130)?
Weekly Report · 02/02 10:32
3 Best Stocks to Buy Today, 1/30/2026, According to Top Analysts
TipRanks · 01/30 13:23
Analysts Are Bullish on Top Healthcare Stocks: Perspective Therapeutics (CATX), Zenas BioPharma, Inc. (ZBIO)
TipRanks · 01/30 12:51
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 01/30 11:30
More
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Webull offers Monopar Therapeutics Inc stock information, including NASDAQ: MNPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNPR stock methods without spending real money on the virtual paper trading platform.